RFI for Biosimilar Insulin Production

Background
The Oklahoma State Department of Health (OSDH) is seeking input from pharmaceutical manufacturers regarding the production of fast-acting biosimilar insulin. This initiative is part of the Insulin Access and Affordability Program established by SB 1344, which was signed into law on May 1, 2026. The program aims to enhance access to affordable insulin for residents of Oklahoma.

Work Details
The RFI seeks information from manufacturers about their plans to produce a low-cost, fast-acting biosimilar insulin without rebates, except as legally required. Manufacturers are asked to provide details on the anticipated timeline for making this product available in Oklahoma, the geographic locations of manufacturing, and the estimated savings for Oklahoma residents and payors. Additionally, if funding under the Insulin Access and Affordability Program is received, manufacturers must indicate whether they have a match of non-state funds.

Period of Performance
The specific period of performance is not defined in this RFI as it is primarily for information gathering; however, manufacturers are expected to outline their timelines for product availability.

Place of Performance
The geographic location(s) where the biosimilar insulin will be manufactured should be described by the responding manufacturers.

Bidder Requirements
Manufacturers must submit a Certification for Competitive Bid and Contract along with their response. They are required to register with the Oklahoma Secretary of State prior to contract award. Additionally, bidders must provide proof of compliance with the Oklahoma Administrative Workers’ Compensation Act through a certificate of insurance. If applicable, service-disabled veteran businesses must include certification and verification documents as specified.